Nanotech treatment gets boost with GSK licensing agreement

Dec 17, 2009

(PhysOrg.com) -- GlaxoSmithKline and Ann Arbor-based NanoBio Corporation announced today that they have signed an exclusive over-the-counter licensing agreement for NanoBio’s unique nanoemulsion treatment for cold sores in the United States and Canada.

James R. Baker, Jr., M.D., director of the Michigan Nanotechnology Institute for Medicine and Biological Sciences at the University of Michigan Medical School, developed nanoemulsions in the 1990s at U-M and founded NanoBio Corporation to further develop and commercialize the technology.

The nanoemulsion technology is patented by U-M and licensed to NanoBio Corporation. Dr. Baker serves as CEO of NanoBio Corporation, where he holds a financial interest. At U-M, he also is the Ruth Dow Doan Professor of Internal Medicine and allergy division chief.

“For the university, this agreement between NanoBio and GlaxoSmithKline demonstrates the value of our technology and fulfills our goal of getting the benefits of our research deployed broadly to the general public,” says Ken Nisbet, executive director of the U-M Office of Technology Transfer.

“We’re very proud of the accomplishments of Dr. Baker and the entire NanoBio team.”

Under the new agreement, New Jersey-based will pay NanoBio an up-front fee of $14.5 million for licensing rights for the nanoemulsion product called NB-001. NanoBio is eligible to receive additional milestone payments of up to $40 million plus high single-digit royalties on future sales.

Nanoemulsions are superfine mixtures of and water, stabilized by surfactants and blended at very high speeds so that the resulting droplets are less than 400 in diameter. Nanoemulsion droplets fuse with a microbe’s outer membrane, disrupt the membrane and kill the organism.

Baker believes that the GlaxoSmithKline-NanoBio partnership will “enable the development and commercialization of NB-001 to its fullest potential and validates the promise of our proprietary platform technology, and its potential use in a wide range of dermatological and anti-infective applications.”

NB-001 is the first nanoemulsion therapeutic to complete successful phase 2 clinical trials and will enter phase 3 testing within the next six months. NanoBio is developing other nanoemulsion-based therapies for a range of diseases including fungal infections, acne and molluscum contagiosum.

Cold sores, caused by the virus herpes labialis, affect about one-fifth of adults in the United States. NB001 will add to GSK’s Abreva line of over-the-counter medications for cold sores.

Explore further: New nanodevice defeats drug resistance

add to favorites email to friend print save as pdf

Related Stories

Nano vaccine for hepatitis B shows promise for third world

Aug 13, 2008

Chronic hepatitis B infects 400 million people worldwide, many of them children. Even with three effective vaccines available, hepatitis B remains a stubborn, unrelenting health problem, especially in Africa and other developing ...

Nanoemulsion vaccines show increasing promise

Feb 26, 2008

A novel technique for vaccinating against a variety of infectious diseases – using an oil-based emulsion placed in the nose, rather than needles – has proved able to produce a strong immune response against ...

Recommended for you

Electrons moving along defined snake states

2 hours ago

Physicists at the University of Basel have shown for the first time that electrons in graphene can be moved along a predefined path. This movement occurs entirely without loss and could provide a basis for ...

New nanodevice defeats drug resistance

19 hours ago

Chemotherapy often shrinks tumors at first, but as cancer cells become resistant to drug treatment, tumors can grow back. A new nanodevice developed by MIT researchers can help overcome that by first blocking ...

Glass coating improves battery performance

20 hours ago

Lithium-sulfur batteries have been a hot topic in battery research because of their ability to produce up to 10 times more energy than conventional batteries, which means they hold great promise for applications ...

User comments : 0

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.